Aripiprazole for the treatment of Tourette syndrome

References

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington (DC): American Psychiatric Publishing; 2013.
   Google Scholar
• Martino D, Cavanna AE, Robertson MM, et al. Prevalence and phenomenology of eye tics in Gilles de la Tourette syndrome. J Neurol. 2012;259:2137–2140.
   PubMed Web of Science ®Google Scholar
• Martino D, Madhusudan N, Zis P, et al. An introduction to the clinical phenomenology of Tourette syndrome. Int Rev Neurobiol. 2013;112:1–33.
   PubMed Web of Science ®Google Scholar
• Cavanna AE, Termine C. Tourette syndrome. Adv Exp Med Biol. 2012;724:375–383.
   PubMed Web of Science ®Google Scholar
• Eddy CM, Cavanna AE. Premonitory urges in adults with complicated and uncomplicated Tourette syndrome. Behav Modif. 2014;38:264–275.
   PubMed Web of Science ®Google Scholar
• Cox JH, Seri S, Cavanna AE. Sensory aspects of Tourette syndrome. Neurosci Biobehav Rev. 2018;88:170–176.
   PubMed Web of Science ®Google Scholar
• Eddy CM, Cavanna AE. ‘It’s a curse!’: coprolalia in Tourette syndrome. Eur J Neurol. 2013;20:1467–1470.
   PubMed Web of Science ®Google Scholar
• Eddy CM, Cavanna AE. On being your own worst enemy: an investigation of socially inappropriate symptoms in Tourette syndrome. J Psychiatr Res. 2013;47:1259–1263.
   PubMed Web of Science ®Google Scholar
• Scharf JM, Miller LL, Gauvin CA, et al. Population prevalence of Tourette syndrome: a systematic review and meta-analysis. Mov Disord. 2015;30:221–228.
   PubMed Web of Science ®Google Scholar
• Robertson MM, Eapen V, Cavanna AE. The international prevalence, epidemiology, and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res. 2009;67:475–483.
   PubMed Web of Science ®Google Scholar
• Hassan N, Cavanna AE. The prognosis of Tourette syndrome: implications for clinical practice. Funct Neurol. 2012;27:23–27.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Gelineau-Kattner R, Davidson A. Tourette’s syndrome in adults. Mov Disord. 2010;25:2171–2175.
   PubMed Web of Science ®Google Scholar
• Zilhão NR, Padmanabhuni SS, Pagliaroli L, et al. Epigenome-wide association study of tic disorders. Twin Res Hum Genet. 2015;18:1–11.
   PubMed Web of Science ®Google Scholar
• Pauls DL, Fernandez TV, Mathews CA, et al. The inheritance of Tourette disorder: a review. J Obsessive Compuls Relat Disord. 2014;3:380–385.
   PubMed Web of Science ®Google Scholar
• O’Rourke JA, Scharf JM, Yu D, et al. The genetics of Tourette syndrome: a review. J Psychosom Res. 2009;67:533–545.
   PubMed Web of Science ®Google Scholar
• Cox JH, Seri S, Cavanna AE. Histaminergic modulation in Tourette syndrome. Expert Opin Orphan Drugs. 2016;4:205–213.
   Web of Science ®Google Scholar
• Rapanelli M, Pittenger C. Histamine and histamine receptors in Tourette syndrome and other neuropsychiatric conditions. Neuropharmacol. 2016;106:85–90.
   PubMed Web of Science ®Google Scholar
• Chao TK, Hu J, Pringsheim T. Prenatal risk factors for Tourette syndrome: a systematic review. BMC Pregnancy Childbirth. 2014;14:53.
   PubMed Web of Science ®Google Scholar
• Martino D, Johnson I, Leckman JF. What does immunology have to do with normal brain development and the pathophysiology underlying Tourette syndrome and related neuropsychiatric disorders? Front Neurol. 2020;11:567407.
   PubMed Web of Science ®Google Scholar
• Robertson MM, Cavanna AE, Eapen V. Gilles de la Tourette syndrome and disruptive behavior disorders: prevalence, associations, and explanation of the relationships. J Neuropsychiatry Clin Neurosci. 2015;27:33–41.
   PubMed Web of Science ®Google Scholar
• Cavanna AE. Gilles de la Tourette syndrome as a paradigmatic neuropsychiatric disorder. CNS Spectr. 2018;23:213–218.
   PubMed Web of Science ®Google Scholar
• Eddy CM, Cavanna AE. Tourette syndrome and obsessive compulsive disorder: compulsivity along the continuum. J Obsessive Compuls Relat Disord. 2014;3:363–371.
   Web of Science ®Google Scholar
• Cooke T, So TY. Attention deficit hyperactive disorder and occurrence of tic disorders in children and adolescents: what is the verdict. Curr Pediatr Rev. 2016;12:230–238.
   PubMed Web of Science ®Google Scholar
• Hirschritt ME, Lee PC, Pauls DL, et al. Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome. JAMA Psychiatry. 2015;72:325–333.
   PubMed Web of Science ®Google Scholar
• Eapen V, Cavanna AE, Robertson MM. Comorbidities, social impact, and quality of life in Tourette syndrome. Front Psychiatry. 2016;7:97.
   PubMed Web of Science ®Google Scholar
• Evans J, Seri S, Cavanna AE. The effects of Gilles de la Tourette syndrome and other chronic tic disorders on quality of life across the lifespan: a systematic review. Eur Child Adolesc Psychiatry. 2016;25:939–948.
   PubMed Web of Science ®Google Scholar
• Cox JH, Nahar A, Termine C, et al. Social stigma and self-perception in adolescents with Tourette syndrome. Adolesc Health Med Ther. 2019;10:75–82.
   PubMed Web of Science ®Google Scholar
• Thomas R, Cavanna AE. The pharmacology of Tourette syndrome. J Neural Transm. 2013;120:689–694.
   PubMed Web of Science ®Google Scholar
• Waldon K, Hill J, Termine C, et al. Trials of pharmacological interventions for Tourette syndrome: a systematic review. Behav Neurol. 2013;26:265–273.
   PubMed Web of Science ®Google Scholar
• Dutta N, Cavanna AE. The effectiveness of habit reversal therapy in the treatment of Tourette syndrome and other chronic tic disorders: a systematic review. Funct Neurol. 2013;28:7–12.
   PubMedGoogle Scholar
• Azrin NH, Nunn RG. Habit reversal: a method of eliminating nervous habits and tics. Behav Res Ther. 1973;11:619–628.
   PubMed Web of Science ®Google Scholar
• Fründt O, Woods D, Ganos C. Behavioral therapy for Tourette syndrome and chronic tic disorders. Neurol Clin Pract. 2017;7:148–156.
   PubMedGoogle Scholar
• Frank M, Cavanna AE. Behavioural treatments for Tourette syndrome: an evidence-based review. Behav Neurol. 2013;27:105–117.
   PubMed Web of Science ®Google Scholar
• McGuire JF, Piacentini J, Brennan EA, et al. A meta-analysis of behavior therapy for Tourette syndrome. J Psychiatr Res. 2014;50:106–112.
   PubMed Web of Science ®Google Scholar
• O’Connor K, Lavoie M, Blanchet P, et al. Evaluation of a cognitive psychophysiological model for management of tic disorders: an open trial. Br J Psychiatry. 2016;209:76–83.
   PubMed Web of Science ®Google Scholar
• Cavanna AE, Eddy CM, Mitchell R, et al. An approach to deep brain stimulation for severe treatment-refractory Tourette syndrome: the UK perspective. Br J Neurosurg. 2011;25:38–44.
   PubMed Web of Science ®Google Scholar
• Schrock LE, Mink JW, Woods DW, et al. Tourette syndrome deep brain stimulation: a review and updated recommendations. Mov Disord. 2015;30:448–471.
   PubMed Web of Science ®Google Scholar
• Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF, et al. Efficacy and safety of deep brain stimulation in Tourette syndrome: the international tourette syndrome deep brain stimulation public database and registry. JAMA Neurol. 2018;75:353–359.
   PubMed Web of Science ®Google Scholar
• Baldermann JC, Schüller T, Huys D, et al. Deep brain stimulation for Tourette syndrome: a systematic review and meta-analysis. Brain Stimul. 2016;9:296–304.
   PubMed Web of Science ®Google Scholar
• Coulombe MA, Elkaim LM, Alotaibi NM, et al. Deep brain stimulation for Gilles de la Tourette syndrome in children and youth: a meta-analysis with individual participant data. J Neurosurg Pediatr. 2018;23:236–246.
   PubMed Web of Science ®Google Scholar
• Xu W, Zhang C, Deeb W, et al. Deep brain stimulation for Tourette’s syndrome. Transl Neurodegener. 2020;9:4.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92:896–906.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Holler-Managan Y, Okun M, et al. Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92:907–915.
   PubMed Web of Science ®Google Scholar
• Cavanna AE. Pharmacological treatment of tics. Cambridge: Cambridge University Press; 2020.
   Google Scholar
• Müller-Vahl KR, Krueger D. Does Tourette syndrome prevent tardive dyskinesia? Mov Disord. 2011;26:2442–3244.
   PubMed Web of Science ®Google Scholar
• Cox JH, Seri S, Cavanna AE. Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders. Pediatric Health Med Ther. 2016;7:57–64.
   PubMed Web of Science ®Google Scholar
• Gulisano M, Calì PV, Cavanna AE, et al. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011;32:1213–1217.
   PubMed Web of Science ®Google Scholar
• Kaur N, Kumar P, Jamwal S, et al. Tetrabenazine: spotlight on drug review. Ann Neurosci. 2016;23:176–185.
   PubMed Web of Science ®Google Scholar
• Nagai Y, Cavanna A, Critchley HD. Influence of sympathetic autonomic arousal on tics: implications for a therapeutic behavioral intervention for Tourette syndrome. J Psychosom Res. 2009;67:599–605.
   PubMed Web of Science ®Google Scholar
• Yang CS, Zhang LL, Zeng LN, et al. Topiramate for Tourette’s syndrome in children: a meta-analysis. Pediatr Neurol. 2013;49:344–350.
   PubMed Web of Science ®Google Scholar
• Hirose T, Kikuchi T. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest. 2005;52:284–290.
   PubMedGoogle Scholar
• Harrison TS, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64:1715–1736.
   PubMed Web of Science ®Google Scholar
• Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol. 2003;28:1400–1411.
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441:137–140.
   PubMed Web of Science ®Google Scholar
• Zhang X, Xiang Q, Zhao X, et al. Association between aripiprazole pharmacokinetics and CYP2D6 phenotypes: a systematic review and meta‐analysis. J Clin Pharm Ther. 2019;44:163–173.
   PubMed Web of Science ®Google Scholar
• Etminan M, Sodhi M, Samii A, et al. Risk of gambling disorder and impulse control disorder with aripiprazole, pramipexole, and ropinirole: a pharmacoepidemiologic study. J Clin Psychopharmacol. 2017;37:102–104.
   PubMed Web of Science ®Google Scholar
• Grall-Bronnec M, Sauvaget A, Perrouin F, et al. Pathological gambling associated with aripiprazole or dopamine replacement therapy: do patients share the same features? A review. J Clin Psychopharmacol. 2016;36:63–70.
   PubMed Web of Science ®Google Scholar
• Lertxundi U, Hernandez R, Medrano J, et al. Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation? Int Clin Psychopharmacol. 2018;33:56–58.
   PubMed Web of Science ®Google Scholar
• Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2016;6:CD009043.
   Google Scholar
• Davies L, Stern JS, Agrawal N, et al. A case series of patients with Tourette’s syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol. 2006;21:447–453.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al.; The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Martino D, Pringsheim TM, Cavanna AE, et al. Systematic review of severity scales and screening instruments for tics: critique and recommendations. Mov Disord. 2017;32:467–473.
   PubMed Web of Science ®Google Scholar
• Storch EA, Murphy TK, Geffken GR, et al. Reliability and validity of the yale global tic severity scale. Psychol Assess. 2005;17:486–491.
   PubMed Web of Science ®Google Scholar
• Yoo HK, Joung YS, Lee JS, et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette’s disorder. J Clin Psychiatry. 2013;74:772–780.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014;45:596–603.
   PubMed Web of Science ®Google Scholar
• Ghanizadeh A. Twice-weekly aripiprazole for treating children and adolescents with tic disorder, a randomized controlled clinical trial. Ann Gen Psychiatry. 2016;15:21.
   PubMed Web of Science ®Google Scholar
• Sallee F, Kohegyi E, Zhao J, et al. Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette’s disorder in children and adolescents. J Child Adolesc Psychopharmacol. 2017;27:771–781.
   PubMed Web of Science ®Google Scholar
• Tao D, Zhong T, Ma S, et al. Randomized controlled clinical trial comparing the efficacy and tolerability of aripiprazole and sodium valproate in the treatment of Tourette syndrome. Ann Gen Psychiatry. 2019;18:24.
   PubMed Web of Science ®Google Scholar
• Yoo HK, Kim JY, Kim CY. A pilot study of aripiprazole in children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol. 2006;16:505–506.
   PubMed Web of Science ®Google Scholar
• Yoo HK, Choi SH, Park S, et al. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry. 2007;68:1088–1093.
   PubMed Web of Science ®Google Scholar
• Seo WS, Sung HM, Sea HS, et al. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol. 2008;18:197–205.
   PubMed Web of Science ®Google Scholar
• Lyon GJ, Samar S, Jummani R, et al. Aripiprazole in children and adolescents with Tourette’s disorder: an open-label safety and tolerability study. J Child Adolesc Psychopharmacol. 2009;19:623–633.
   PubMed Web of Science ®Google Scholar
• Murphy TK, Mutch PJ, Reid JM. Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol. 2009;19:441–447.
   PubMed Web of Science ®Google Scholar
• Cui YH, Zheng Y, Yang YP, et al. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette’s disorder: a pilot study in China. J Child Adolesc Psychopharmacol. 2010;20:291–298.
   PubMed Web of Science ®Google Scholar
• Yoo HK, Lee JS, Paik KW, et al. Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders. Eur Child Adolesc Psychiatry. 2011;20:127–135.
   PubMed Web of Science ®Google Scholar
• Masi G, Gagliano A, Siracusano R, et al. Aripiprazole in children with Tourette’s disorder and co-morbid attention-deficit/hyperactivity disorder: a 12-week, open-label, preliminary study. J Child Adolesc Psychopharmacol. 2012;22:120–125.
   PubMed Web of Science ®Google Scholar
• Ho CS, Chiu NC, Tseng CF, et al. Clinical effectiveness of aripiprazole in short-term treatment of tic disorder in children and adolescents: a naturalistic study. Pediatr Neonatol. 2014;55:48–52.
   PubMed Web of Science ®Google Scholar
• Wang LJ, Chou WJ, Chou MC, et al. The effectiveness of aripiprazole for tics, social adjustment, and parental stress in children and adolescents with Tourette’s disorder. J Child Adolesc Psychopharmacol. 2016;26:442–448.
   PubMed Web of Science ®Google Scholar
• Gerasch S, Kanaan A, Jakubovski E, et al. Aripiprazole improves associated comorbid conditions in addition to tics in adult patients with Gilles de la Tourette Syndrome. Front Neurosci. 2016;10:416.
   PubMed Web of Science ®Google Scholar
• Kawohl W, Schneider F, Vernaleken I, et al. Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients. World J Biol Psychiatry. 2009;10:827–831.
   PubMed Web of Science ®Google Scholar
• Wenzel C, Kleimann A, Bokemeyer S, et al. Aripiprazole for the treatment of Tourette syndrome: a case series of 100 patients. J Clin Psychopharmacol. 2012;32:548–550.
   PubMed Web of Science ®Google Scholar
• Neuner I, Nordt C, Schneider F, et al. Effectiveness of aripiprazole in the treatment of adult Tourette patients up to 56 months. Hum Psychopharmacol. 2012;27:364–369.
   PubMed Web of Science ®Google Scholar
• Rothenberger A, Roessner V. Psychopharmacotherapy of obsessive-compulsive symptoms within the framework of Tourette syndrome. Curr Neuropharmacol. 2019;17:703–709.
   PubMed Web of Science ®Google Scholar
• Budman C, Coffey BJ, Shechter R, et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol. 2008;18:509–515.
   PubMed Web of Science ®Google Scholar
• Masi G, Pfanner C, Brovedani P. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study. J Psych Res. 2013;47:1007–1012.
   Web of Science ®Google Scholar
• Janik P, Szejko N. Aripiprazole in treatment of Gilles de la Tourette syndrome: new therapeutic option. Neurol Neurochir Pol. 2018;52:84–87.
   PubMed Web of Science ®Google Scholar
• Quezada J, Coffman KA. Current approaches and new developments in the pharmacological management of Tourette syndrome. CNS Drugs. 2018;32:33–45.
   PubMed Web of Science ®Google Scholar
• Coustals N, Ménard ML, Cohen D. Aripiprazole in children and adolescents. J Child Adolesc Psychopharmacol. in press;2021;31:4-32.
   Google Scholar
• Iasevoli F, Barone A, Buonaguro EF, et al. Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review. Expert Opin Drug Saf. 2020;19:1419–1444.
   PubMed Web of Science ®Google Scholar
• Billnitzer A, Jankovic J. Current management of tics and Tourette syndrome: behavioral, pharmacologic, and surgical treatments. Neurotherapeutics. 2020;17:1681–1693.
   PubMed Web of Science ®Google Scholar
• Yang C, Yi Q, Zhang L, et al. Safety of aripiprazole for tics in children and adolescents: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e15816.
   PubMed Web of Science ®Google Scholar
• Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20:173–196.
   PubMed Web of Science ®Google Scholar
• Cavanna AE, Rickards H, Worrall R, et al. From ipse dixit to evidence-based guidelines: on the optimal management of Tourette syndrome. Eur J Paediatr Neurol. 2012;16:310–311.
   PubMed Web of Science ®Google Scholar
• Rickards H, Cavanna AE, Worrall R. Treatment practices in Tourette syndrome: the European perspective. Eur J Paediatr Neurol. 2012;16:361–364.
   PubMed Web of Science ®Google Scholar
• Pringsheim T, Doja A, Gorman D, et al. Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry. 2012;57:133–143.
   PubMed Web of Science ®Google Scholar
• Cothros N, Martino D, McMorris C, et al. Prescriptions for alpha agonists and antipsychotics in children and youth with tic disorders: a pharmacoepidemiologic study. Tremor Other Hyperkinet Mov. 2019;9.
   PubMed Web of Science ®Google Scholar
• Murphy TK, Lewin AB, Storch EA, et al. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. J Am Acad Child Adolesc Psychiatry. 2013;52:1341–1359.
   PubMed Web of Science ®Google Scholar
• Hollis C, Pennant M, Cuenca J, et al. Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis. Health Technol Assess. 2016;20:1–450.
   PubMed Web of Science ®Google Scholar
• Whittington C, Pennant M, Kendall T, et al. Treatments for Tourette syndrome in children and young people: a systematic review. J Child Psychol Psychiatry. 2016;57:988–1004.
   PubMed Web of Science ®Google Scholar
• Hamamoto Y, Fujio M, Nonaka M, et al. Expert consensus on pharmacotherapy for tic disorders in Japan. Brain Dev. 2019;41:501–506.
   PubMed Web of Science ®Google Scholar
• Badenoch J, Cavanna AE. Pharmacotherapy for tics in adult patients with Tourette syndrome and other tic disorders. Neurol Sci. 2020;41:1923–1926
   PubMed Web of Science ®Google Scholar